Europe
Janssen’s Erleada expanded in Europe to cover metastatic hormone-sensitive prostate cancer
January 29, 2020Research and Development, Sales and Marketing Erleada, Europe, Janssen, pharma
Janssen’s Erleada (apalutamide) has secured expanded authorisation from the European Commission (EC), approving its label to include the treatment of …
European Commission expands Stelara for paediatric moderate to severe plaque psoriasis
January 24, 2020Research and Development Europe, Janssen, Stelara, pharma
Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis …
European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma
November 20, 2019Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma
Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
November 18, 2019Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes
November 15, 2019Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes
Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …
Expanded EU label for Benlyta now covers paediatric lupus patients
October 30, 2019Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma
GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …
“No deal” Brexit and life sciences: What happens?
October 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma
Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …
Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation
September 24, 2019Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma
September 4, 2019Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer
August 30, 2019Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq
Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …
Janssen chalks up two more indications in Europe for Imbruvica combo therapies
August 14, 2019Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma
Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …
Sanofi’s Dupixent extended in Europe to cover adolescents in atopic dermatitis
August 6, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Sanofi, atopic dermatits, pharma
Sanofi has announced that European Commission (EC) has chosen to extend the marketing approval of its interleukin-4 (IL-4) and interleukin-13 …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
